Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02444637|
Recruitment Status : Unknown
Verified May 2015 by Dr Nagaendran Kandiah, National Neuroscience Institute.
Recruitment status was: Recruiting
First Posted : May 14, 2015
Last Update Posted : May 14, 2015
Rivastigmine, an acetylcholinesterase inhibitor which has been approved by FDA & HSA, is authorized for use in the treatment of mild to moderate dementia of the Alzheimer's type.
In this trial, the investigators will be studying the effectiveness of Rivastigmine in subjects with AD and cerebrovascular disease.
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer Disease CVA (Cerebrovascular Accident)||Drug: Rivastigmine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage Alzheimer's Disease Having Coexisting Small Vessel Cerebrovascular Disease|
|Study Start Date :||April 2015|
|Estimated Primary Completion Date :||April 2017|
Experimental: Rivastigmine (Exelon) Patch
For the first 4 weeks of the study, subjects will receive Rivastigmine patch 4.6mg/24 hours. Thereafter, subjects will receive Rivastigmine patch 9.5mg/24 hours.
Other Name: Exelon
- Number of Participants with Demonstrated Benefit in Global and Cognitive Measures [ Time Frame: 2 Years ]
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 2 Years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02444637
|Contact: Jocelyn Cheong||(65) email@example.com|
|National Neuroscience Institute||Recruiting|
|Singapore, Singapore, 308433|
|Contact: Jocelyn Cheong (65) 63577635 firstname.lastname@example.org|
|Principal Investigator: Nagaendran Kandiah, MRCP;FAMS|